CYTK Cytokinetics Inc

Price (delayed)

$59.68

Market cap

$6.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.4

Enterprise value

$6.89B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by ...

Highlights

Cytokinetics's quick ratio has decreased by 21% YoY but it has increased by 16% from the previous quarter

Cytokinetics's gross profit has plunged by 96% YoY and by 50% from the previous quarter

The revenue has dropped by 96% year-on-year and by 50% since the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.cytokinetics.com

Peers: ABIO LGND TRVN ARRY

Key stats

What are the main financial stats of CYTK

Market

Shares outstanding

104.85M

Market cap

$6.26B

Enterprise value

$6.89B

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

1,621.22

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,837.05

Earnings

Revenue

$3.75M

EBIT

-$502.15M

EBITDA

-$489.78M

Free cash flow

-$422.57M

Per share

EPS

-$5.4

Free cash flow per share

-$4.15

Book value per share

-$3.85

Revenue per share

$0.04

TBVPS

$7.93

Balance sheet

Total assets

$808.08M

Total liabilities

$1.2B

Debt

$754.92M

Equity

-$396.16M

Working capital

$549.85M

Liquidity

Debt to equity

-1.91

Current ratio

7.19

Quick ratio

6.98

Net debt/EBITDA

-1.3

Margins

EBITDA margin

-13,053.7%

Gross margin

100%

Net margin

-14,141.7%

Operating margin

-13,272%

Efficiency

Return on assets

-67.3%

Return on equity

N/A

Return on invested capital

-37%

Return on capital employed

-69.8%

Return on sales

-13,383.5%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

CYTK stock price

How has the Cytokinetics stock price performed over time

Intraday

2.02%

1 week

5.8%

1 month

15.32%

1 year

84.2%

YTD

-28.52%

QTD

10.15%

Financial performance

How have Cytokinetics's revenue and profit performed over time

Revenue

$3.75M

Gross profit

$3.75M

Operating income

-$497.97M

Net income

-$530.6M

Gross margin

100%

Net margin

-14,141.7%

The net margin has plunged by 102% from the previous quarter

Cytokinetics's operating margin has plunged by 101% from the previous quarter

Cytokinetics's gross profit has plunged by 96% YoY and by 50% from the previous quarter

The revenue has dropped by 96% year-on-year and by 50% since the previous quarter

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation

P/E

N/A

P/B

N/A

P/S

1,621.22

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1,837.05

The EPS has contracted by 17% YoY

CYTK's equity has dropped by 73% year-on-year and by 2.5% since the previous quarter

The revenue has dropped by 96% year-on-year and by 50% since the previous quarter

CYTK's P/S is 74% above its last 4 quarters average of 912.7

Efficiency

How efficient is Cytokinetics business performance

The ROS has plunged by 102% from the previous quarter

The company's return on assets fell by 47% YoY and by 3.4% QoQ

CYTK's return on invested capital is down by 28% year-on-year and by 2.8% since the previous quarter

Dividends

What is CYTK's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time

The total assets is 33% smaller than the total liabilities

Cytokinetics's quick ratio has decreased by 21% YoY but it has increased by 16% from the previous quarter

The company's current ratio fell by 21% YoY but it rose by 17% QoQ

CYTK's equity has dropped by 73% year-on-year and by 2.5% since the previous quarter

Cytokinetics's debt to equity has increased by 42% YoY and by 2.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.